Artal Group’s Editas Medicine EDIT Stock Holding History

Artal Group’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-25,000	Closed	-$829K	–	107
2018 Q1	$829K	Sell	25,000 -25,000	-50%	-$891K	0.01%	107
2017 Q4	$1.54M	Buy	+50,000	New	+$1.26M	0.02%	103

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group's EDIT Position: Q2 2018 in Review

Artal Group sold out of Editas Medicine (EDIT) in Q2 2018, closing a stake of 25,000 shares — an estimated $829K sold.

Artal Group first reported a position in EDIT in Q4 2017 and held it in 2 quarters. The position peaked at $1.54M in Q4 2017. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2018.

Artal Group reported no remaining Editas Medicine position as of Q2 2018 after selling out during the quarter.
Artal Group sold 25,000 Editas Medicine shares in Q2 2018, an estimated $829K.
Artal Group first reported a position in Editas Medicine in Q4 2017 and held it in 2 quarters.
Artal Group's Editas Medicine position peaked at $1.54M in Q4 2017.
215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2018.

Based on Artal Group's 13F filing for Q2 2018, filed 10 Aug 2018.